My laboratory research to date has focused on the design, cloning, production, and use of lentiviruses in vitro and in vivo to overexpress or knock down gene expression, particularly in alveolar macrophages and stem cell populations, and using lentiviruses to develop a gene therapy for alpha-1 antitrypsin deficiency. I have approached this problem through the manipulation of two target cell populations: hematopoietic stem cells and alveolar macrophages. Both approaches have resulted in long-term expression of human alpha-1 antitrypsin in laboratory animals. In addition to the in-vivo overexpression of alpha-1 antitrypsin, I am interested in manipulating other genes which may play a role in the pathogenesis of COPD, such as NF-kB.
A second area of interest is embryonic stem cell biology. I am working with Darrell Kotton and others in our division to study the progression of definitive endoderm to lung epithelium.
Research interests include:
-Alpha-1 antitrypsin deficiency
-alveolar macrophage biology
-embryonic stem cells
Clinical interests include:
-Critical Care Medicine
- Active Staff Privileges, Pulmonary, Allergy, Sleep & Critical Care Medicine, Medicine, Boston Medical Center
- University of Texas Southwestern Medical School, MD
- Williams College, BA
- Published on 10/15/2018
Reeves EP, O'Dwyer CA, Dunlea DM, Wormald MR, Hawkins P, Alfares M, Kotton DN, Rowe SM, Wilson AA, McElvaney NG. Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med. 2018 Oct 15; 198(8):1099-1102. PMID: 30011228.
- Published on 9/15/2018
Kaserman JE, Wilson AA. Patient-Derived Induced Pluripotent Stem Cells for Alpha-1 Antitrypsin Deficiency Disease Modeling and Therapeutic Discovery. Chronic Obstr Pulm Dis. 2018 Sep 15; 5(4):258-266. PMID: 30723783.
- Published on 7/21/2018
Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018 Sep; 25(3):148-155. PMID: 30032658.
- Published on 6/5/2018
Segeritz CP, Rashid ST, de Brito MC, Serra MP, Ordonez A, Morell CM, Kaserman JE, Madrigal P, Hannan NRF, Gatto L, Tan L, Wilson AA, Lilley K, Marciniak SJ, Gooptu B, Lomas DA, Vallier L. hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in a1-antitrypsin deficiency. J Hepatol. 2018 Oct; 69(4):851-860. PMID: 29879455.
- Published on 8/15/2017
Coleman FT, Blahna MT, Kamata H, Yamamoto K, Zabinski MC, Kramnik I, Wilson AA, Kotton DN, Quinton LJ, Jones MR, Pelton SI, Mizgerd JP. Capacity of Pneumococci to Activate Macrophage Nuclear Factor ?B: Influence on Necroptosis and Pneumonia Severity. J Infect Dis. 2017 Aug 15; 216(4):425-435. PMID: 28368460.
- Published on 4/10/2017
Pastore N, Attanasio S, Granese B, Castello R, Teckman J, Wilson AA, Ballabio A, Brunetti-Pierri N. Activation of the c-Jun N-terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin. Hepatology. 2017 Jun; 65(6):1865-1874. PMID: 28073160.
- Published on 1/1/2017
Kaserman JE, Wilson AA. Protocol for Directed Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) to a Hepatic Lineage. Methods Mol Biol. 2017; 1639:151-160. PMID: 28752455.
- Published on 6/29/2016
Payne JG, Takahashi A, Higgins MI, Porter EL, Suki B, Balazs A, Wilson AA. Multilineage transduction of resident lung cells in vivo by AAV2/8 for a1-antitrypsin gene therapy. Mol Ther Methods Clin Dev. 2016; 3:16042. PMID: 27408904.
- Published on 4/13/2015
Tafaleng EN, Chakraborty S, Han B, Hale P, Wu W, Soto-Gutierrez A, Feghali-Bostwick CA, Wilson AA, Kotton DN, Nagaya M, Strom SC, Roy-Chowdhury J, Stolz DB, Perlmutter DH, Fox IJ. Induced pluripotent stem cells model personalized variations in liver disease resulting from a1-antitrypsin deficiency. Hepatology. 2015 Jul; 62(1):147-57. PMID: 25690322.
- Published on 4/2/2015
Wilson AA, Ying L, Liesa M, Segeritz CP, Mills JA, Shen SS, Jean J, Lonza GC, Liberti DC, Lang AH, Nazaire J, Gower AC, Müeller FJ, Mehta P, Ordóñez A, Lomas DA, Vallier L, Murphy GJ, Mostoslavsky G, Spira A, Shirihai OS, Ramirez MI, Gadue P, Kotton DN. Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells. Stem Cell Reports. 2015 May 12; 4(5):873-85. PMID: 25843048.
View 9 more publications: View full profile at BUMC